Repligen
RGEN
#2434
Rank
A$11.02 B
Marketcap
A$195.47
Share price
-5.84%
Change (1 day)
11.15%
Change (1 year)
Categories

Repligen (RGEN) - Total liabilities

Total liabilities on the balance sheet as of March 2026 : A$1.17 Billion

According to Repligen 's latest financial reports the company's total liabilities are A$1.17 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Repligen - Total liabilities on balance sheet (from 2001 to 2026)

Total liabilities by year

Year Total liabilities Change
2025-12-31A$1.25 B-8.59%
2024-12-31A$1.37 B8.35%
2023-12-31A$1.27 B39.37%
2022-12-31A$0.91 B8.74%
2021-12-31A$0.83 B72.62%
2020-12-31A$0.48 B-0.01%
2019-12-31A$0.48 B115.31%
2018-12-31A$0.22 B15.98%
2017-12-31A$0.19 B16.78%
2016-12-31A$0.16 B416.95%
2015-12-31A$32.24 M59.34%
2014-12-31A$20.23 M22.3%
2013-12-31A$16.54 M33.44%
2012-12-31A$12.39 M
2011-03-31A$5.03 M-12.46%
2010-03-31A$5.75 M-13.12%
2009-03-31A$6.62 M28.94%
2008-03-31A$5.13 M17.36%
2007-03-31A$4.37 M-2.4%
2006-03-31A$4.48 M4.49%
2005-03-31A$4.29 M31.98%
2004-03-31A$3.25 M-12.53%
2003-03-31A$3.71 M-25.6%
2002-03-31A$4.99 M92.2%
2001-03-31A$2.6 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Pfizer
PFE
A$167.25 B 14,102.44%๐Ÿ‡บ๐Ÿ‡ธ USA
Thermo Fisher Scientific
TMO
A$87.35 B 7,317.83%๐Ÿ‡บ๐Ÿ‡ธ USA
General Electric
GE
A$157.17 B 13,246.27%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
A$94.70 B 7,942.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
A$0.11 B-90.02%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
A$1.69 B 43.94%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
A$2.13 B 81.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Bio-Techne
TECH
A$0.66 B-43.62%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
A$3.39 B 188.24%๐Ÿ‡บ๐Ÿ‡ธ USA
Charles River Laboratories
CRL
A$6.76 B 474.57%๐Ÿ‡บ๐Ÿ‡ธ USA